Yüklüyor......
2493. Real-World Utilization of Ibalizumab (IBA) Without an Optimized Background Regimen (OBT)
BACKGROUND: It is difficult to treat multidrug-resistant (MDR) human immunodeficiency virus (HIV). Trogarzo® (ibalizumab) a novel monoclonal antibody was approved in 2018 for heavily treatment-experienced HIV patients. Data support IBA use with at least one fully active agent, an OBR. Real-world IBA...
Kaydedildi:
| Yayımlandı: | Open Forum Infect Dis |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809681/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2171 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|